Navigation Links
David Norton Appointed to TB Alliance's Board of Directors
Date:3/4/2013

NEW YORK, March 4, 2013 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the mission of developing better, faster-acting, and affordable TB treatments, announces the election to its Board of Directors of David Norton , former Company Group Chairman of Global Pharmaceuticals for Johnson & Johnson (J&J). Mr. Norton brings to TB Alliance nearly 40 years of experience within the pharmaceutical sector, and is noted for his strategy in charting the growth of J&J's pharmaceuticals group.

"Tuberculosis research is on the verge of delivering incredible breakthroughs," said Mr. Norton. "I am committed to leveraging my experience in global product development and commercialization to enhance the impact of such crucial efforts and help stop the TB pandemic."

Throughout his career, Mr. Norton has helped lead J&J's efforts around research and development, commercial operations, licensing, and acquisitions. Now retired, he serves as Chairman of the Board of Directors of the American Foundation for Suicide Prevention. He is a member of the Board of Directors of Savient and recently served as interim CEO. Previously, Mr. Norton served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Alliance for Aging Research.

Dr. Carlos Morel , Chairman of the Board for TB Alliance and Director of the Center for Technological Development in Health (CDTS) of FIOCRUZ, remarked, "Mr. Norton's appointment to the TB Alliance's Board of Directors will expand the organization's knowledge — from developing new TB drug regimens to now ensuring widespread access to them. Mr. Norton's deep experience in shepherding new treatments to global markets will help the TB Alliance achieve its mission."

Tuberculosis (TB) is a global pandemic, killing someone approximately every 25 seconds — nearly 1.4 million in 2011 alone. The WHO estimates that two billion people — one third of the world's population — are infected with Mycobacterium tuberculosis (M.tb), the bacillus that causes the disease. Today's TB drug regimens take too long to cure, are complicated to administer, and can be toxic.  New drug regimens are critical to drastically reduce the global TB burden and to stop the growth and spread of drug-resistant forms of the disease.

About TB Alliance:
The Global Alliance for TB Drug Development (TB Alliance) is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. The TB Alliance operates with funding from the Bill & Melinda Gates Foundation, Irish Aid , UK aid, UNITAID, National Institute of Allergy and Infectious Disease, the United States Agency for International Development, and the United States Food and Drug Administration, and the United States AIDS Clinical Trials Group. For more information, please visit tballiance.org.

Contact:

Joanna Breitstein
TB Alliance
(m) 646.616.8613
Joanna.breitstein@tballiance.org


'/>"/>
SOURCE TB Alliance
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. David F. Harty Joins Systech International as Vice President
2. Dr. David Brailer and Stephen Dubner Keynotes for NYeC 2012 Digital Health Conference
3. WebMD Taps David C. Marek to Assume Consumer Leadership Role
4. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
5. Alliqua Names David Johnson Executive Chairman of Aquamed Technologies and Member of Alliqua Board of Directors
6. Herb Baer Appointed President of Polar USA
7. New Executive Vice President Commercial Appointed
8. Israel Makov Appointed Chairman of Sun Pharma Board
9. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
10. Neal K. Long appointed as Chief Executive Officer at Cardiac Science
11. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... Mass. and SAN CLEMENTE, Calif. , ... California -based mobile pulmonary function testing company, is now able ... PFT devices developed by ndd Medical Technologies , Inc. ... testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® ... , can get any needed testing done in the comfort ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):